Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2022.01.03.22268681: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources While anti-nucleocapsid antibody is indicative of prior or current SARS-CoV-2 infection, anti-spike protein antibody may be induced either by SARS-CoV-2 infection or by COVID-19 vaccination (including the three vaccines authorized in the United States). anti-nucleocapsidsuggested: Noneanti-spike proteinsuggested: (GeneTex Cat# GTX632604, RRID:AB_2864418)Persons who met these criteria and tested positive for anti-spike antibody were also considered to have no laboratory evidence of SARS-CoV-2 infection as anti-spike … SciScore for 10.1101/2022.01.03.22268681: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources While anti-nucleocapsid antibody is indicative of prior or current SARS-CoV-2 infection, anti-spike protein antibody may be induced either by SARS-CoV-2 infection or by COVID-19 vaccination (including the three vaccines authorized in the United States). anti-nucleocapsidsuggested: Noneanti-spike proteinsuggested: (GeneTex Cat# GTX632604, RRID:AB_2864418)Persons who met these criteria and tested positive for anti-spike antibody were also considered to have no laboratory evidence of SARS-CoV-2 infection as anti-spike antibody was presumed to be vaccine-derived. anti-spikesuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:In addition, given the limitations of laboratory assays and detection sensitivities of each test, some of the six cases may have been infected with SARS-CoV-2 in the recent past, and vaccination may be coincidental to the subsequent MIS-C illness. Children often have unrecognized SARS-CoV-2 infection associated with mild or absent symptoms.3, 5 Persons with mild or asymptomatic illness may be less likely to generate anti-nucleocapsid antibody, and anti-nucleocapsid antibody from prior infection wanes over time, particularly in those with mild infection.8, 24, 25 These limitations could lead to misclassification of SARS-CoV-2 infection status. In addition to the six persons without evidence of SARS-CoV-2 infection, we identified three others who met clinical and inflammatory criteria and did not have evidence of SARS-CoV-2 infection but did not meet MIS-C case definition because anti-spike antibody was not obtained. Neither MIS-C nor multisystem inflammatory syndrome in adults (MIS-A) was reported in the clinical trials of COVID-19 vaccines used in the United States.14, 26 Globally, MIS-C following COVID-19 vaccination has been reported in the literature for six persons <21 years of age.23, 27-30 Two of these persons are from the United States and are included in our case series; both had evidence of SARS-CoV-2 infection.23 A third reported person from the United States had received dose two of the Pfizer-BioNTech vaccine two months prior to presentation and had evidence of in...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
